![](https://kascope.com/wp-content/uploads/2024/07/Eyevensys-Sketch-Pages_BLK-e1721068007262.jpg)
PulseSight (Formally Eyevensys) approached Kaleidoscope’s ID team with the following need:
“Help us develop and train ophthalmologists on how to perform our innovative electrotransfection procedure.”
Unlike most pharmaceuticals that treat conditions of the eye, PulseSight’s non-viral gene therapy teaches the eye to heal itself. Very cool stuff!
So, Kaleidoscope’s designers got to work, collaborating with surgeons, practicing the procedure in situ, not only illustrating but also developing techniques for the procedure itself. The final procedure guide and accompanying trainer helped ensure PulseSight’s clinical trial progressed even more smoothly.
![](https://kascope.com/wp-content/uploads/2024/07/Screenshot-2024-07-11-at-4.37.56 PM-e1721067693882-300x170.png)
![](https://kascope.com/wp-content/uploads/2024/07/Screenshot-2024-07-11-at-4.18.55 PM-e1721068268233-300x200.png)
“Sunny” is the nickname for the anatomical model Kaleidoscope’s design and engineering team developed to train retinal surgeons on the innovative new Electrotransfection Gene Therapy pioneered by PulseSight.
To properly prepare surgeons for the novel obstacles experienced in the procedure, Kaleidoscope’s team of designers created this model to accurately simulate limited orbital access and the rotational effects of the rectus muscles of the human eye.
While Sunny doesn’t talk much, he definitely has seen a lot!
As experts in the field of Ophthalmic drug delivery devices, Kaleidoscope's team helped redesign the product from the ground up, improving the overall usability of the device and the efficacy and accuracy of the drug delivery.
![Surface Studio On Table Mockup by Anthony Boyd Graphics](https://kascope.com/wp-content/uploads/2024/07/Eyevensys-CAD-View-e1721068487177-300x170.jpg)
![](https://kascope.com/wp-content/uploads/2024/07/Eyevensys-Procedure_01_v2-e1721068805358-300x200.jpg)
Learn more here: https://kascope.com/case-study/pulsesight-therapeutics/
Back to Insights + News